Centene Corporation operates as a diversified and multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. It operates through two segments, Managed Care and Specialty Services. The Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term care, foster care, and dual eligible individual, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray services, home-based primary care, transportation assistance, vision care, dental care, immunizations, prescriptions and limited over-the-counter drugs, specialty pharmacy, therapies, social work services, and care coordination. The Specialty Services segment provides pharmacy benefits management services; health, triage, wellness, and disease management services; vision and dental services; correctional healthcare services; home based primary care services; and integrated long-term care services, as well as care management software that automate the clinical, administrative, and technical components of care management programs. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, military service members and their families, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Hospital & medical service plans
Sub-IndustryManaged Health Care
SectorMedical
Current SymbolNYSE:CNC
Previous Symbol
CUSIP15135B10
Phone314-725-4477
Debt
Debt-to-Equity Ratio0.59
Current Ratio1.03
Quick Ratio1.03
Price-To-Earnings
Trailing P/E Ratio18.95
Forward P/E Ratio18.12
P/E Growth1.21
Sales & Book Value
Annual Sales$48.38 billion
Price / Sales0.54
Cash Flow$7.2419 per share
Price / Cash Flow17.61
Book Value$39.78 per share
Price / Book3.21
Profitability
EPS (Most Recent Fiscal Year)$5.03
Net Income$828 million
Net Margins1.58%
Return on Equity14.42%
Return on Assets4.84%
Miscellaneous
Employees33,700
Outstanding Shares205,350,000
Market Cap$26.19 billion
OptionableOptionable
Centene (NYSE:CNC) Frequently Asked Questions
What is Centene's stock symbol?
Centene trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNC."
How were Centene's earnings last quarter?
Centene Corp (NYSE:CNC) posted its quarterly earnings results on Tuesday, October, 23rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.02. The company had revenue of $16.18 billion for the quarter, compared to analyst estimates of $15.93 billion. Centene had a net margin of 1.58% and a return on equity of 14.42%. The company's quarterly revenue was up 36.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.35 earnings per share. View Centene's Earnings History.
When is Centene's next earnings date?
What guidance has Centene issued on next quarter's earnings?
Centene issued an update on its FY19 earnings guidance on Thursday, December, 13th. The company provided EPS guidance of $8.15 to $8.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.36. The company issued revenue guidance of $69.7 billion to $70.5 billion, compared to the consensus revenue estimate of $70.10 billion.Centene also updated its FY18 guidance to $6.90 to $7.10 EPS.
What price target have analysts set for CNC?
14 brokerages have issued 1 year target prices for Centene's shares. Their predictions range from $115.00 to $175.00. On average, they expect Centene's stock price to reach $151.1914 in the next year. This suggests a possible upside of 18.6% from the stock's current price. View Analyst Price Targets for Centene.
What is the consensus analysts' recommendation for Centene?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Centene in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Centene.
What are Wall Street analysts saying about Centene stock?
Here are some recent quotes from research analysts about Centene stock:
- 1. Cantor Fitzgerald analysts commented, "We rate Centene Corporation (CNC) DCF-based price target of $145 per share. We continue to view Medicaid as a good growth opportunity. At the same time, CNC is building its Medicare Advantage business, increasing its footprint in individual exchange markets (and doing it profitably) and increasing its specialty offerings. $145 per share 12-month price target is based on DCF analysis." (12/13/2018)
- 2. According to Zacks Investment Research, "Centene’s third-quarter earnings of $1.79 beat the Zacks Consensus Estimate by 1.1% and grew 32.6% year over year. Earnings gained from the acquisition of Fidelis Care, growth in the health insurance marketplace business, expansion in new programs in many of its states, other acquisitions including MHM, CMG, and Foundation Care, and the return of the health insurer fee in 2018. Expansion of Marketplace business and a number of Medicaid and Medicare contract wins should lead to membership growth. Its strong cash flow generation capacity aids investment in business. The stock has outperformed its industry in a year’s time. The increase in earnings guidance for 2018 instills investor’s confidence in the company. Nevertheless, increasing operating costs, high leverage levels, and increase in interest costs are concerns." (10/25/2018)
Has Centene been receiving favorable news coverage?
Media coverage about CNC stock has trended somewhat positive this week, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Centene earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are some of Centene's key competitors?
Who are Centene's key executives?
Centene's management team includes the folowing people:
- Mr. Michael Frederic Neidorff, Chairman & CEO (Age 75)
- Ms. Cynthia J. Brinkley, Pres , COO, Chief Admin. & Markets Officer (Age 58)
- Mr. Jeffrey Alan Schwaneke CPA, CPA, Exec., CFO & Treasurer (Age 42)
- Mr. Keith Harvey Williamson, Exec. VP, Gen. Counsel & Corp. Sec. (Age 66)
- Mr. Jesse N. Hunter, Exec. VP & Chief Strategy Officer (Age 42)
Who are Centene's major shareholders?
Centene's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc (9.93%), Vanguard Group Inc. (9.93%), BlackRock Inc. (8.19%), Capital World Investors (4.95%), Capital International Investors (3.41%) and JPMorgan Chase & Co. (1.54%). Company insiders that own Centene stock include Brandy Burkhalter, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Mark J Brooks, Michael F Neidorff, Richard A Gephardt, Robert K Ditmore and Stephen Wallace. View Institutional Ownership Trends for Centene.
Which major investors are selling Centene stock?
CNC stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, AQR Capital Management LLC, Vanguard Group Inc., Vanguard Group Inc, Panagora Asset Management Inc., LSV Asset Management, Redmile Group LLC and Mitsubishi UFJ Trust & Banking Corp. Company insiders that have sold Centene company stock in the last year include Brandy Burkhalter, Christopher D Bowers, Jesse N Hunter, Keith H Williamson, Michael F Neidorff and Robert K Ditmore. View Insider Buying and Selling for Centene.
Which major investors are buying Centene stock?
CNC stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, FMR LLC, BlackRock Inc., Franklin Resources Inc., Point72 Asset Management L.P., Alliancebernstein L.P., Morgan Stanley and Rehmann Capital Advisory Group. View Insider Buying and Selling for Centene.
How do I buy shares of Centene?
Shares of CNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Centene's stock price today?
One share of CNC stock can currently be purchased for approximately $127.53.
How big of a company is Centene?
Centene has a market capitalization of $26.19 billion and generates $48.38 billion in revenue each year. The company earns $828 million in net income (profit) each year or $5.03 on an earnings per share basis. Centene employs 33,700 workers across the globe.
What is Centene's official website?
How can I contact Centene?
Centene's mailing address is 7700 FORSYTH BOULEVARD, ST LOUIS MO, 63105. The company can be reached via phone at 314-725-4477 or via email at [email protected]
MarketBeat Community Rating for Centene (NYSE CNC)
MarketBeat's community ratings are surveys of what our community members think about Centene and other stocks. Vote "Outperform" if you believe CNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
